Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.010740439381611 -0.00569568755085438
Stock impact report

FDA allowed Athenex's IND application of Eribulin ORA to begin clinical trials [Seeking Alpha]

Athenex, Inc. (ATNX) 
Last athenex, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.athenex.com
Company Research Source: Seeking Alpha
Athenex (NASDAQ: ATNX ) announces that the FDA has allowed the IND application for it's oral version of Eribulin currently named Eribulin ORA. This FDA action allows Athenex to commence its clinical trial program, currently planned for H1 2019. Eribulin, an effective treatment for metastatic breast cancer and liposarcoma, is currently limited to intravenous administration. Click to subscribe to real-time analytics on ATNX Now read: Daily Insider Ratings Round-Up 10/15/18 » Subscribe for full text news in your inbox Show less Read more
Impact Snapshot
Event Time:
ATNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ATNX alerts
Opt-in for
ATNX alerts

from News Quantified
Opt-in for
ATNX alerts

from News Quantified